Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

3 clinical studies listed.

Filters:

High-Risk Localized Prostate Cancer

Tundra lists 3 High-Risk Localized Prostate Cancer clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT07862582

RYZ711 Diagnostic Platform Study

This is a Phase 1/2 multicenter, multi-cohort imaging study to evaluate the safety, tolerability, and diagnostic performance of RYZ711 positron emission tomography/computed tomography (PET/CT) in men with histologically confirmed adenocarcinoma of the prostate.

Gender: MALE

Ages: 18 Years - Any

Updated: 2026-11-12

1 state

Prostate Cancer (Adenocarcinoma)
Adenocarcinoma of the Prostate
Metastatic Castration-resistant Prostate Cancer (mCRPC)
+3
NOT YET RECRUITING

NCT07924605

PSMA PET/MRI for Predicting and Detecting Prostate Cancer

The goal of this clinical trial is to see if a drug called 18F-DCFPyL can help find prostate cancer or prostate cancer that has spread to other parts of the body. The main question it aims to answer is: * Can 18F-DCFPyL predict response to therapy; and, * Does 18F-DCFPyL improve detection of early signs of cancer. Participants will undergo PET/MRI scans.

Gender: MALE

Ages: 18 Years - 85 Years

Updated: 2026-11-09

1 state

Prostate Cancer
High-Risk Localized Prostate Cancer
Locally Advanced Prostate Cancer
+2
RECRUITING

NCT07550517

PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

This research is being done to find out if the study drug, 177Lu-PSMA-617, given before and during standard of care External Beam Radiation Therapy (EBRT) treatment, with a shorter course of Androgen Deprivation Therapy (ADT) (6 months) is (1) safe and effective compared to standard of care alone, and (2) can reduce the side effects caused by long-term (24 months) ADT in men with high risk localized prostate cancer.

Gender: MALE

Ages: 18 Years - Any

Updated: 2026-09-22

1 state

High-Risk Localized Prostate Cancer